THE MCMANUS GROUP

Lobbying for GILEAD SCIENCES, INC. · Client is a biopharmaceutical company that develops medicines in areas of unmet need.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $60,000.00 income · posted Apr 21, 2025

Bills named in this filing 1

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 2

Medicare/Medicaid

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Support for EPIC Act - H.R. 1492

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.